Conflict of interests
In the past 3 years, SL declares having received research grants from
Astra Zeneca and Santelys, remunerations for symposiums by Sanofi and
Novartis.
FA declares personal fees for consulting, lectures or boards from
Stallergenes Greer, ALK, AImmune Therapeutics, GSK, Novartis, and
Sanofi.
AD declares consultancy or speaker fees from Novartis, GSK, Sanofi,
Regeneron, AstraZeneca, Aimmune Therapeutics, DBV Technologies, Nestlé
Health Science, ALK, Stallergènes-Greer outside the submitted work.
GL declares remunerations for symposia from DBV Technologies, Aimmune
Therapeutics, for conferences from Novartis Pharma, Astra Zeneca, ALK,
board consulting for ALK, Stallergenes-Greer, Aimmune Therapeutics,
advices for Meenuts, expert consulting for ALK, Stallergenes-Greer.